Search Results - "Reznichenko, Nataliya"
-
1
49140 Clinical similarity of SB17 (Proposed Ustekinumab Biosimilar) to Reference Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis: Randomized, Double-blind, Phase III, 52-Week Results
Published in Journal of the American Academy of Dermatology (01-09-2024)Get full text
Journal Article -
2
MAIN AGE-RELATED CUTANEOUS CHANGES IN MEN GROUNDED ON THE RESULTS OF ULTRASONIC DIAGNOSTICS
Published in Eastern Ukrainian medical journal (18-06-2023)“…Introduction. An extremely important task of modern medical science is to preserve the health of the population. Various age violations are found in men, such…”
Get full text
Journal Article -
3
A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis
Published in Journal of the American Academy of Dermatology (01-09-2024)“…Ustekinumab (UST) is a safe and effective treatment for moderate-to-severe psoriasis. To compare efficacy, safety, pharmacokinetics (PK), and immunogenicity of…”
Get full text
Journal Article -
4
Assessing the Interchangeability of AVT02 and Humira® in Participants with Moderate‑to‑Severe Chronic Plaque Psoriasis: Pharmacokinetics, Efficacy, Safety, and Immunogenicity Results from a Multicenter, Double-Blind, Randomized, Parallel-Group Study
Published in BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy (01-07-2023)“…Background The US Food and Drug Administration (FDA) interchangeability guidelines state that the primary endpoint in a switching study should assess the…”
Get full text
Journal Article -
5
Ex vivo comparative immunogenicity assessment (EVCIA) to determine relative immunogenicity in chronic plaque psoriasis in participants receiving Humira® or undergoing repeated switches between Humira® and AVT02
Published in Immunotherapy advances (01-01-2024)“…Summary Immunogenicity against biologic medicines is ubiquitous, and it is traditionally measured by the final humoral response. However, the onset of a…”
Get full text
Journal Article -
6
Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study
Published in BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy (01-11-2021)“…Background AVT02 (adalimumab) is a proposed biosimilar to Humira ® . AVT02 is produced at a 100 mg/mL concentration with a citrate-free formulation. Objectives…”
Get full text
Journal Article -
7
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study
Published in BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy (01-01-2024)“…Background CT-P43 is a candidate ustekinumab biosimilar in clinical development. Objectives This paper aims to demonstrate equivalent efficacy of CT-P43 to…”
Get full text
Journal Article -
8
Learning Intermediate Algebra with Graphing Calculator in Community College: A Study of Graphing Calculator Implementation
Published 2012“…Since technology has taken its place in almost all classrooms in schools and colleges across the country, there is a need to know how technology influences the…”
Get full text
Dissertation -
9
Learning intermediate algebra with graphing calculator in community college: A study of graphing calculator implementation
Get full text
Dissertation